# Interleukin-36 upregulates type-I interferon responses in systemic lupus erythematosus by promoting the accumulation of self-nucleic acids

**Authors:** Emma J. Welsh, Daniel McCluskey, Patrick Baum, Myles J. Lewis, Francesca Capon

PMC · DOI: 10.3389/fimmu.2025.1727524 · 2026-01-13

## TL;DR

This study shows that IL-36 increases type-I interferon responses in lupus by causing monocyte apoptosis and reducing self-nucleic acid clearance.

## Contribution

The novel finding is that IL-36 promotes self-nucleic acid accumulation in SLE through monocyte apoptosis and RNAse downregulation.

## Key findings

- IL-36 treatment upregulates IRF7-driven type-I IFN pathways in classical monocytes.
- IL-36 downregulates RNAse genes and increases monocyte apoptosis, leading to self-nucleic acid accumulation.
- IL-36 activity correlates with IRF7 activity in SLE monocytes (r=0.35, P=0.02).

## Abstract

Several studies have reported an up-regulation of interleukin (IL)-36 in the serum of patients with systemic lupus erythematosus (SLE). Here, we sought to define the mechanisms whereby IL-36 may contribute to the over-activation of type I Interferon (IFN) responses observed in SLE.

We carried out single-cell (sc)RNA-seq in healthy peripheral blood mononuclear cells treated with IL-36 (n=5 donors). We compared the genes and transcriptional networks that were induced by IL-36 with those that were upregulated in a published SLE scRNA-seq dataset (n=33 cases and 11 controls). In follow-up studies, we validated the effects of IL-36 on monocytes by real-time PCR (n=9 donors) and flow-cytometry (n=6).

Classical monocytes were the immune population most affected by IL-36 treatment (n=203 Differentially Expressed Genes). In these cells, IL-36 upregulated transcriptional networks (regulons) driven by IRF7, a key activator of type I IFN responses. A similar upregulation of IRF7 regulons was observed in the monocytes of SLE cases, where measurements of IL-36 and IRF7 activity were significantly correlated (r=0.35, P = 0.02). Experimental follow-up studies in human monocytes showed that IL-36 downregulates multiple RNAse genes (RNASE1, RNASE6, RNASET2). IL-36 treatment of monocytes also increased the percentage of apoptotic cells (45% vs 37% in untreated cells; P = 0.001), which are a critical source of self-nucleic acids.

We find that IL-36 promotes monocyte apoptosis while downregulating self-nucleic acid clearance. Thus, IL-36 contributes to the accumulation of self-nucleic acids, a key driver of type I IFN responses in SLE.

## Linked entities

- **Genes:** IRF7 (interferon regulatory factor 7) [NCBI Gene 3665], RNASE1 (ribonuclease A family member 1, pancreatic) [NCBI Gene 6035], RNASE6 (ribonuclease A family member 6) [NCBI Gene 6039], RNASET2 (ribonuclease T2) [NCBI Gene 8635]
- **Proteins:** LOC101448341 (ribonuclease kappa-B-like)
- **Diseases:** systemic lupus erythematosus (MONDO:0007915), SLE (MONDO:0007915)

## Full-text entities

- **Genes:** RNASE1 (ribonuclease A family member 1, pancreatic) [NCBI Gene 6035] {aka RAC1, RIB1, RNS1}, IRF7 (interferon regulatory factor 7) [NCBI Gene 3665] {aka IMD39, IRF-7, IRF-7H, IRF7A, IRF7B, IRF7C}, RNASE6 (ribonuclease A family member 6) [NCBI Gene 6039] {aka RAD1, RNS6, RNasek6}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, RNASET2 (ribonuclease T2) [NCBI Gene 8635] {aka RNASE6PL, bA514O12.3}
- **Diseases:** SLE (MESH:D008180)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12835401/full.md

---
Source: https://tomesphere.com/paper/PMC12835401